ARTICLE | Clinical News
Recombinant platelet factor 4: Started Phase I/II trial
October 4, 1993 7:00 AM UTC
Repligen Corp. (RGEN) Product: Recombinant platelet factor 4 (rPF4), an inhibitor of new blood vessel networks Indication: Kaposi's sarcoma Status: Started three open-label trials: a Phase II trial o...